CXCR6 is a chemokine receptor and the primary coreceptor in SIV infection. A single nucleotide polymorphism 1469G-A, results in a nonconservative change in codon 3 (CXCR6-E3K) of the N-terminus of the coreceptor. To investigate the relation between the chemokine receptor CXCR6 genotype and progression to Pneumocystis carinii pneumonia (PCP) and from PCP to death, we clinically assessed and genotyped 805 individuals from an African-American injection drug-using cohort in Baltimore, MD, USA, for this CXCR6-E3K polymorphism. The allele frequency of CXCR6-3K was high (44%) in African Americans and rare in European Americans (fo1%). Although time to AIDS and PCP was similar for all CXCR6 genotypes, the median survival time from PCP to death for the CXCR6-3E/E and CXCR6-3E/K genotype was 1.5 years compared to 3.1 years for the CXCR6-K/K genotype. Individuals homozygous or heterozygous for the CXCR6-3E allele were 5.6 times more likely to die a PCP-mediated AIDS-related death than were individuals homozygous for CXCR6-3K. This study shows an association between CXCR6 genotype and progression from PCP to death among African-Americans with HIV. We suggest that CXCR6 may play a role in late-stage HIV-1 infection and may alter the progression to death after initial infection with PCP.
Introduction
In the past few years, there have been multiple discoveries demonstrating the importance of host genetics in modulating HIV-1 infection and progression to clinical AIDS. Focus has concentrated on the chemokine receptors and chemokines involved in early stages of infection, such as viral binding and entry. Host genetic factors in genes encoding chemokine receptors and their ligands and in HLA class I antigen-presenting molecules have been associated with variation in susceptibility or resistance to HIV-1 infection and in progression to AIDS especially in predominantly white cohorts (for reviews see Michael 1 , O'Brien and Moore 2 and O'Brien et al 3 ). However, their role in African-American cohorts has been minimal because of lower allele frequencies. [4] [5] [6] Assessing the role of CCR5 and CXCR4 in AIDS pathogenesis is critical since the majority of HIV-1 strains utilize these receptors. However, the utilization of secondary coreceptors may also be important particularly in the dynamic adaptive advances that occur as HIV-1 disease progresses. Additionally, an understanding of later stages of clinical HIV-1 infection may help explain the rapid progression to death after AIDS diagnosis, and the onset of opportunistic infections. AIDS is a compilation of opportunistic infections (OIs) and malignancies, and there is limited understanding of the role of host genetics on these OIs and malignancies.
A G-coupled seven-transmembrane receptor, CXCR6 (also termed STRL33/BONZO/TYMSTR), has gained interest as another portal for HIV-1 entry because it is a principal coreceptor for SIV. [7] [8] [9] [10] CXCR6, is a secondary coreceptor for HIV that can mediate fusion of HIV-1 to CD4
+ cells with HIV-1 envelope from M-tropic and dualtropic strains, and CXCR6 enhances HIV-1 infectivity, suggesting a potential role in progression of HIV-1. 8 Additionally, the chemokine and ligand for CXCR6, CXCL16 is highly expressed in lung and chemotactic to CD4 + T cells. 11 Furthermore, CXCR6+ T cells are prevalent in tissue sites of inflammation and preferentially expressed by Th1 cells, making it a candidate gene for OIs and malignancies. 12 Since clinical AIDS is a composite of OIs and malignancies, it is not clear if genetic variants associated with receptors and chemokines control progression to AIDS or time to a specific OI or malignancy. One of the most prevalent OIs in our cohort is the lung infection, Pneumocystis carinii pneumonia (PCP). Thus, we chose to investigate the effects of a novel nonconservative acidic to basic change in the third codon of the extracellular domain of CXCR6 on time to death after a clinical diagnosis of PCP in a cohort of African-American HIVpositive injection drug users (IDUs). Based on these data, we suggest that another chemokine receptor, CXCR6, may play a role in progression to death and may help to explain late-stage HIV pathogenesis involving PCP infection.
Results
A total of 805 people were followed including 198 seroincident and 607 seroprevalent IDUs. The median time of follow-up for this cohort was 8.5 years. The mean time of entry into the study for this cohort was August 1988 and this did not differ by CXCR6 genotype among either seroincidents or seroprevalents. The median time from AIDS 1993 diagnosis to AIDS-related death and time from initial PCP to AIDS-related death was 1.4 and 2.2 years, respectively.
PCP was identified as a primary AIDS diagnosis in 18% of all seroincident and 19% of seroprevalent individuals. PCP accounted for 24% of all OIs and malignancies in this cohort, which together with esophageal candidiasis (24%) was the most frequent, followed by recurrent pneumonia (13%), and Mycobacterium avium infection (12%). Among CXCR6-genotyped individuals with an initial diagnosis of PCP (n ¼ 60), there were 36 deaths, all AIDS related. Overall, there were 351 deaths (228 AIDS related and 123 non-AIDS related) among CXCR6-genotyped individuals. The AIDS-related deaths included AIDS-defining complication (181), sepsis (23), bacterial pneumonia (12), endocarditis (8) , and pulmonary disease (3). There were 123 non-AIDS-related causes of death, including 49 owing to drug overdose and 17 owing to trauma. All deaths attributable to cancer were non-AIDS related. In the cohort, 9% reported any use of highly active antiretroviral therapy (HAART); however, only 1.7% reported use of HAART on at least two consecutive visits. Under both definitions, the frequency of HAART was evenly distributed over genotype (any HAART, w 2 ¼ 1.65, P-value ¼ 0.44; two consecutive HAART, w 2 ¼ 2.44, P-value ¼ 0.30). No individual reporting at least two consecutive treatments of HAART died from an AIDSrelated illness during the period of follow-up. HAART was associated with the final outcome (death), but not the exposure (genotype), and was therefore not included as a confounder in subsequent analysis. 13 The CXCR6-E3K (1469-A, GAG-AAG) mutation in codon 3 results in a nonconservative replacement of a negatively charged to a positively charged R group of the first extracellular domain of the N-terminus of the coreceptor. A total of 262 individuals (32%) were homozygous CXCR6-3E/3E, 384 (48%) were heterozygous CXCR6-3E/3K, and 159 (20%) were homozygous for the CXCR6-3K/3K genotype. This cohort showed no deviation from Hardy-Weinberg equilibrium for the three genotypes. The CXCR6-3K allele frequency was 44% (n ¼ 702/1610) among these African American. In a separate analysis of cohorts of European Americans, the CXCR6-3K allele frequency was o1% (C Winkler, personal communication), thus we could not assess effects of the CXCR6 3K variant among European Americans because of low statistical power. Table 1 shows the characteristics of the cohort by CXCR6 genotype.
The effect of the CXCR6 genotype on progression to PCP and AIDS was assessed by Cox proportional hazards analyses assuming a recessive genetic model, where CXCR6 3K/3K homozygotes were compared to the other two genotypes. The univariate and multivariate analyses showed no statistically significant effect of genotype for any AIDS definition ( Table 2 ). The CXCR6 3K/3K genotype did not affect the rate of progression to AIDS or progression to the PCP as an outcome.
We then tested whether the CXCR6 genotype influenced later stages of HIV infection. Specifically, we analyzed the survival after diagnosis of PCP (Table 3) . Comparing Kaplan-Meier survival curves showed that the median survival time from PCP to death for CXCR6-3E/3E and CXCR6-3E/3K genotype was 1.5 years (n ¼ 48) compared to 3.1 years (n ¼ 12) for the CXCR6-3K/3K genotype ( Figure 1 ). In an adjusted Cox model, the relative hazard (RH) from PCP to death showed a highly protective effect of CXCR6-3K/3K genotypes (RH ¼ 0.18, CI: 0.05, 0.56, P-value ¼ 0.003). In the univariate model, the RH suggested a protective effect of genotype, but this was only of marginal statistical significance (RH ¼ 0.37, CI: 0.13, 1.06, P-value ¼ 0.07). The relative risk of death for those with the CXCR6-3K/ 3K genotype was half the risk of those who carried at least one CXCR6-3E allele.
Since HAART has a profound effect on mortality and no individual on HAART died of an AIDS-related illness in this cohort, it is important to assess its effect. However, HAART was evenly distributed across CXCR6 genotypes and could not be considered a confounder. In a restricted Cox model that only included individuals reporting never using HAART, the RH from PCP to death continued to show a delayed progression to death among those with the CXCR6-3K/3K genotype (n ¼ 42, adjusted RH ¼ 0.30, CI: 0.08, 1.07). Among those individuals not reporting any use of HAART, this resulted in a median survival time for those with at least one CXCR6-3E allele of 1.3 years compared to 2.2 years for homozygotes for CXCR6-3K. Additionally, we performed a Cox analysis with a censoring date of July 1, 1997 (prior to the use of any HAART in this cohort) among 48 individuals who had PCP. There was a statistically significant delayed progression to death among those with the CXCR6-3K/3K genotype (adjusted RH ¼ 0.26, CI: 0.08, 0.86), this further supports the protective role of the CXCR6-3K/3K genotype prior to the use of HAART.
To determine whether the CXCR6 genotype influence extended to the late-stage disease among all AIDS patients (including non-PCP patients), we analyzed survival after diagnosis of AIDS according to the AIDS-87 and AIDS-93 definitions as well as (Table 3) . A marginally protective trend seen here was consistent for adjusted RH for all three AIDS definitions, but none were statistically significant. Additionally, we analyzed survival after diagnosis of esophageal candidiasis, another common OI in this cohort with sufficient numbers of events for analysis. However, there was no association between survival and CXCR6-3K/3K genotype (adjusted RH: 1.03, CI: 0.37, 2.83). These observations suggest that the CXCR6 protective effect may predominantly influence progression from PCP to death.
Discussion
In this study, we show that CXCR6-3K homozygosity increases the length of time from initial AIDS diagnosis of PCP to death in a cohort of African-American IDUs. Individuals homozygous or heterozygous for the CXCR6-3E allele were 5.6 times more likely to die after PCP as the first AIDS-defining illness than were individuals homozygous for CXCR6-3K. This translates to a median survival time of 3.1 years for subjects homozygous for this polymorphism compared to 1.5 years for CXCR6-3E homozygotes and heterozygotes. Although this apparent protective effect from PCP diagnosis to death was consistent among individuals homozygous for CXCR6-3K, the relative hazards analysis using a more inclusive AIDS definition to death were not statistically significant (Table 3 ). The consideration of other OIs and malignancies in the model may have diluted the primary association with PCP. Additionally, the protective effect of the CXCR6-3K/3K genotype was not evident when examining rates of progression to PCP or to any AIDS diagnosis. These observations suggest a specificity of the CXCR6-3K/3K protective influence between onset of PCP and time of mortality.
Mechanisms related specifically to the recovery from PCP may account for the different rates of survival among the CXCR6 genotypes. Since the CXCR6 1469-A SNP results in the replacement of an acidic with a basic amino-acid residue in the third codon of the first extracellular domain, it is possible that affinity for the HIV-1 envelope and/or its ligand is altered. CXCL16, the chemokine and ligand for CXCR6, is highly expressed in lung, and the receptor and ligand may be involved in chronic inflammation. 11 Since we did not see any difference in susceptibility to PCP by CXCR6 genotype, our study suggests that the mechanism for developing PCP is different from the mechanism required for recovering from PCP. Susceptibility to PCP may be the result of a low T-cell count, while recovery from PCP may depend on recruiting T cells to the site of infection. A recent study has determined that CXCR6 is preferentially expressed in Th1 cells in blood, and it may be important in trafficking of T cells that mediate Th1 responses. 12 Host defense mechanisms against PCP are not well defined, but mouse models have shown that In addition, high levels of CCR5 and CXCR6 are expressed on both resting and activated natural killer T (NKT) cells. 15 CXCR6+ NKT cells that have been activated by antigenic exposure are targeted by HIV-1 and more rapidly depleted by R5-using HIV. 15 It is plausible that the specificity of PCP (compared to esophageal candidiasis) activates CCR5+/CXCR6+ NKT cells making them susceptible to infection, and the CXCR6-E3K polymorphism prohibits this activation and subsequent susceptibility.
The CXCR6-3K/3K genotype could delay progression to death from PCP by delaying the decline of CD4 + cells. However, after including either baseline CD4 + cells/mm 3 or CD4 + o200 cells/mm 3 in the model, the protective effect of CXCR6-3K/3K persisted and time to CD4 + o200 cell/mm 3 in individuals with and without the CXCR6-3K/3K genotype progressed similarly (Table 2) .
Additionally, CXCR6 may be involved in HIV-1 pathogenesis by direct HIV coreceptor interaction, and the differential effects of the CXCR6 genotypes may result from altered binding kinetics between HIV-1 env and the coreceptor. Although CCR5 and CXCR4 are primary coreceptors, studies do indicate that HIV-1 can use CXCR6 as a coreceptor on primary cells. 16 As the HIV-1 virus shifts from R5 to X4 in the late stages of infection, the envelope glycoprotein may interact with CXCR6 and use it as a coreceptor since it can mediate fusion by both macrophage and T-cell line tropic HIV-1 strains. 8 Although no specific mechanism for CXCR6 in PCP or HIV-1 pathogenesis has been determined, this study suggests some role for this chemokine receptor. The high allele frequency (44%) among African Americans and the significant protective influence on progression to death after PCP requires further investigation, especially in other African-American or native African cohorts that may have similar allele frequencies. Further studies are needed to elucidate the specific role of CXCR6 as a chemokine receptor in late stages of HIV-1 infection, specifically after infection with PCP, which may be amenable to effective treatment.
Materials and methods

Study population
From February 1988 to March 1989, IDUs were recruited and screened for HIV antibodies from the Baltimore community and invited to join the AIDS Link to the Intravenous Experience (ALIVE), a prospective cohort Adjusted for CCR5 and CCR2 genotypes, age, gender, PCP prophylaxis/treatment and CD4 count at baseline. RH=relative hazards, CI=95% confidence interval.
CXCR6 variant and HIV progression P Duggal et al study as described previously. 17 Participants were considered eligible if they were at least 18 years old, engaged in injection drug use within the previous 10 years, and had not experienced an AIDS defining illness. All study and consent procedures were approved by the Institutional Review Board of the Johns Hopkins School of Public Health.
Data collection
At each semiannual follow-up visit, participants underwent interviewer-administered questionnaires pertaining to sociodemographics, drug use, and sexual practices in the previous 6 months. A trained physician or physician's assistant performed a physical examination including a brief neurologic exam. Any signs and symptoms of HIV-related conditions, sexually transmitted diseases, and injection drug use were recorded for all HIV-infected persons. Health care utilization and HIV-related illnesses were also systematically obtained through medical record review. Deaths were identified through review of vital records and the National Death Index.
Between 1988 and 1997, HIV seroincidents were identified whereby a last HIV-negative test and a first HIV-positive test were recorded. Blood samples were sent to the Laboratory of Genomic Diversity, National Cancer Institute, Frederick, Maryland for genetic testing. This included all samples from the first available seropositive visit from every seroincident subject. A total of 805 African-American subjects with CXCR6 genotyping were included in this analysis.
Genotype assessment
Genomic DNA was obtained from lymphoblastoid cell lines established for each study participant. The alleles for CXCR6-1469G-T (E3K) were determined by using a forced polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) assay. The primer sequences were forward 5 0 -CTATTTGCCCCCTAAATGT-3 0 and reverse 5 0 -CATAGTCTTCATGGTAATCAAGC-3 0 . A Hind III site was introduced by the T to A substitution at the third position to the 3 0 end of the reverse primer. The 145 bp PCR product for the variant CXCR6 K allele was cleaved into 121 and 24 bp fragments by Hind III (New England Biolabs) using standard PCR conditions. The CXCR6-3E allele produced a single 145-bp PCR fragment. PCR products after digestion were visualized in 4% agarose gels. The genomic position is numbered according to Daugherty and Springer 18 accession number U 73531; CXCR6 E3K, nucleotide 1469G/A.
Statistical analysis w
2 Statistics were used to test for differences in allele frequencies, genotype, and Hardy-Weinberg equilibrium between groups. In our preliminary analysis, we evaluated two genetic models where the heterozygote was assumed to be identical to one or another homozygote, that is, dominant (3E/3E ¼ 0, 3E/3K ¼ 1, 3K/ 3K ¼ 1) and recessive (3E/3E ¼ 0, 3E/3K ¼ 0, 3K/3K ¼ 1). Initial analyses of our data suggested a recessive model, so the CXCR6-3E/3E homozygotes and CXCR6-3E/3K heterozygotes were grouped together and compared to CXCR6-3K/3K. Seroincidents were defined as individuals who seroconverted during the study. Dates of seroconversion were estimated as the midpoint between the last negative and first positive visit. Seroprevalents were defined as individuals who were HIV positive at study entry. We defined PCP based on semiannual visits and medical chart review. In addition, we used three AIDS end points: the Centers for Disease Control (CDC) 1987 definition for AIDS, CDC 1993 definition for AIDS and CD4 + o200 cells/mm 3 . 19, 20 Since death among HIV-1 immunosuppressed IDUs may be attributable to non-AIDS-related factors, we restricted our definition of death to AIDS-related deaths (eg AIDS-defining diagnosis, sepsis, endocarditis, and bacterial pneumonia), as previously described. 21 Subjects were censored at last semiannual study visit if they had not developed an event on or before 31 January, 2001. We also did an additional analysis with subjects censored at last semiannual study visit if they had not developed an event on or before July 1, 1997 (prior to the use of highly active antiretroviral treatment, HAART, in this population). We defined HAART using the 2001 HIV/AIDS Figure 1 Kaplan-Meier survival estimates from PCP to death, by CXCR6 genotype. Kaplan-Meier survival distribution curves of HIV-1 disease progression to death after initial diagnosis of PCP. Median survival for CXCR6-3E/3E was 1.4 years, CXCR6-3E/3K was 1.7 years, and CXCR6-3K/3K was 3.1 years. (a) Individual unadjusted survival curves for CXCR6-3E/3E (n ¼ 17), CXCR6-3E/ 3K (n ¼ 31), and CXCR6-3K/3K (n ¼ 12). The P-value was 0.16 from the logrank test (RH: 0.17, 95% CI: 0.04, 0.66). (b) Unadjusted survival curves for CXCR6-3E/3E (n ¼ 17) and CXCR6-3E/3K (n ¼ 31) were grouped together because a similar pattern of progression was observed among these two groups compared to CXCR6-3K/3K (n ¼ 12). The P-value was 0.05 from the logrank test (RH: 0.18, 95% CI: 0.05, 0.56).
treatment recommendations by the DHHS/Kaiser Panel for adult nonpregnant patients with HIV/AIDS. 22 An individual was considered to be on HAART if they reported one of the following criteria: (1) Enhanced HAART regimen, three or more nucleoside reverse transcriptase inhibitors (NRTIs) (2) NRTI HAART regimen, two NRTIs and either 1 or 2 protease inhibitors (PI) or 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), or (3) PI HAART regimen, at least one PI. Since it is difficult to determine commitment to a regimen, we also included a more restricted definition of HAART that required two consecutive self-reports of HAART. Progression to each end point was evaluated using Kaplan-Meier survival curves.
Cox proportional hazard regression models were used to calculate the relative risks of developing AIDS and PCP in relation to CXCR6 genotypes, stratified by seroincident vs seroprevalent serostatus. Among seroincident and seroprevalent individuals, follow-up time was determined from the estimated date of seroconversion (midpoint between last seronegative and first seropositive visits) or date of entry into the study to the date of event/censoring date. Follow-up time to death was determined from the date of AIDS or PCP to date of infectious disease death among both groups. The analyses were repeated after adjusting for covariates in the regression models including age (years), gender (female vs male), CD4+ cell counts at baseline, CCR5 D 32genotypes, and CCR2-V64I genotypes, all of which have been reported to affect HIV/AIDS disease progression. Additionally, since our study was focused on PCP, we included PCP prophylaxis and treatment since use was widespread and both would affect the outcomes of PCP and death. All analyses were conducted using the statistical software STATA v6.0 (College Station, TX, USA).
